On August 1 2023, NEVRO CORP ($NYSE:NVRO) revealed their financial results for the second quarter of FY2023 ending on June 30 2023. Total revenue rose 4.4% year-on-year to USD 108.8 million and net income improved slightly to -24.7 million from the prior year’s figure of -25.0 million.
On Tuesday, NEVRO CORP reported its earnings results for the second quarter of fiscal year 2023. The company’s stock opened at $24.6 and closed at $24.7, a decrease of 1.3% from the previous closing price of 25.0. NEVRO CORP also reported robust cash flows for the quarter ending June 30, 2023. This strong financial performance was primarily driven by the company’s ability to effectively manage costs and reduce its debt levels.
Overall, these results are a positive indication of NEVRO CORP’s financial health and performance in the second quarter of fiscal year 2023. The company will continue to focus on managing its costs in order to maintain strong cash flow and maximize shareholder value. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Nevro Corp. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Nevro Corp. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Nevro Corp. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Nevro Corp are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Nevro Corp Intrinsic Stock Value
At GoodWhale, we believe in taking a deep dive into the fundamentals of stocks before investing. So, we decided to take a look at NEVRO CORP. After conducting our analysis, we have concluded that the fair value of a NEVRO CORP share is around $93.7. This was calculated using our proprietary Valuation Line which takes into account market trends, financial performance, and other factors. In contrast, NEVRO CORP is currently trading at $24.7 – a massive 73.6% undervaluation from its true worth. This could be a great opportunity for investors to purchase shares of NEVRO CORP at an unbeatable price. More…
Risk Rating Analysis
Star Chart Analysis
The company’s competitors include NuVasive Inc, InspireMD Inc, and Inspire Medical Systems Inc.
NuVasive Inc is a medical device company that develops, manufactures, and markets minimally-invasive surgical products for the spine. As of 2022, the company has a market capitalization of $2.22 billion and a return on equity of -1.33%. The company’s products are used in spine surgeries including lumbar decompression, lumbar fusion, and cervical spine fusion.
InspireMD Inc is a medical device company that focuses on the development and commercialization of its proprietary microNet stent platform technology for the treatment of coronary and peripheral artery disease. As of 2022, its market cap is 9.49M and its ROE is -38.62%. The company’s microNet stent is a small mesh tube that is placed over the arterial lesion and is designed to improve blood flow and reduce the risk of clotting. The microNet stent is made of a biocompatible metal alloy and is coated with a thin layer of polymer. The company’s products are CE marked and are available in Europe, the Middle East, and Latin America.
– Inspire Medical Systems Inc ($NYSE:INSP)
Inspire Medical Systems Inc is a company that focuses on sleep apnea treatment. The company has a market cap of 5.97B as of 2022 and a ROE of -11.49%. The company’s products are available in over 30 countries and its products have been used by over 1 million patients.
Investors may be interested in NEVRO CORP’s latest financial results for the second quarter of FY2023, which ended June 30, 2023. Total revenue increased by 4.4% year over year to USD 108.8 million, while net income improved slightly to USD -24.7 million from the prior year’s figure of USD -25.0 million. This suggests that the company is making progress in returning to profitability and may be a good investment option for investors who are looking for a potential turnaround play in the healthcare sector.